23.07.2015 • News • Mergers & Acquisitions (M&A) • Ardian • chemical intermediates

Ardian Acquires ES and IM from DPx Holdings

Austrian private equity investor Ardian has acquired Exclusive Synthesis (ES) and Maleic Anhydride Intermediates & Specialties (IM) from Linz-based DPx Holdings for an undisclosed sum.

The assets held by the 51:49 joint venture of investor JLL Partners and Dutch chemical Group DSM were merged in 2013 from holdings of DSM Pharmaceutical Products and Patheon.

ES develops and produces chemical intermediates for agriculture and other industries. IM produces maleic anhydride, along with a large number of intermediates, derivatives and esters. Together they reported sales of some €200 million in 2014.

With Ardian’s support, management led by designated CEO Wolfgang Hillisch plans to “significantly strengthen” the units’ market position and expand through organic growth and acquisitions.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Top-Feature